- Maribo Medico has been ResMed’s exclusive distribution partner in Denmark for more than 15 years.
- ResMed Maribo will help improve the lives for more of Denmark’s estimated 760,000 people with obstructive sleep apnea (OSA) and 400,000 suffering from chronic obstructive pulmonary disease (COPD).
SAN DIEGO, Calif. – November 12–ResMed (NYSE:RMD) today announced it has acquired Maribo Medico, a privately-held company specializing in the education, diagnosis, treatment and management of sleep-disordered breathing and respiratory diseases. Maribo Medico is Denmark’s market leader in providing sleep-disordered breathing medical devices and accessories.
“Maribo Medico’s strong team and talented leadership, their market reputation, and their commitment to research and education for sleep and respiratory medicine have helped tens of thousands of people in Denmark who suffer from sleep-disordered breathing and chronic obstructive pulmonary disease,” said Anne Reiser, president of ResMed EMEA-APAC. “Maribo and ResMed together will accelerate growth while improving patient quality-of-life and reducing total healthcare system costs in Denmark. This combination is part of our global goal of improving 20 million lives by 2020.”
Maribo Medico employees, including Chief Executive Officer Mette Toxværd Larsen, will continue on in their current roles.
“We are very happy to join with ResMed to help even more people who suffer from sleep-disordered breathing or chronic respiratory diseases,” said Mette Toxværd, CEO of Maribo Medico. “We’ve had a strong and fruitful partnership with ResMed for more than 15 years, and now we will leverage their global strength to improve many more lives in Denmark as ResMed Maribo, building our position in respiratory care and digital, tele-monitoring solutions.”
Financial terms of the transaction were not disclosed.
About Maribo Medico
Founded in 2007 and based in Sjaelland, Denmark, Maribo Medico is Denmark’s leading value-added distributor specializing in providing quality products, compliance and education related to the diagnosis, treatment and management of sleep disordered breathing and respiratory diseases.
The global team at ResMed (NYSE:RMD) is united in the commitment to change millions of lives with every breath. With more than 4,000 employees and a presence in over 100 countries, the company has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit www.resmed.com or follow @resmed on Twitter.
For News Media
Global Corporate Communications
Senior Director, Investor Relations
+1 (858) 836-5971